Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;27(6):313–320. doi: 10.1002/clc.4960270603

The decision to anticoagulate: Assessing whether benefits outweigh the risks for patients with atrial fibrillation

Geno Merli 1,✉, Howard H Weitz 2
PMCID: PMC6654400  PMID: 15237688

Abstract

In a review of relevant articles from the Medline database on stroke risk in atrial fibrillation (AF) and adverse events related to anticoagulation treatment, we found that research to date shows a major potential benefit of warfarin therapy (International Normalized Ratio [INR] 2.0–3.0) for patients with AF (68% risk reduction in primary stroke prevention with warfarin vs. placebo). Despite this highly significant reduction in stroke risk, fewer than 50% of eligible patients are treated, in many cases because of fears of intracranial hemorrhage (ICH). The decision to implement anticoagulant therapy to improve outcome requires balancing the decreased risk for stroke against the increased risk for ICH. Various methods have been developed to define patient‐specific stroke risk. In contrast, risk for ICH strongly correlates with the intensity of anticoagulation, which is an unpredictable but controllable variable requiring frequent dose adjustments. Recent studies have also identified subgroups of patients with neurologic pathologies who are at increased risk for ICH. However, when the INR is properly controlled, the benefit from anticoagulation therapy for patients with AF and other risk factors for stroke exceeds the risk for ICH. Careful monitoring of anticoagulation and warfarin dose titration to maintain the INR between 2.0 and 3.0 is critical for reducing the risk for ICH, as is excluding patients with neurologic conditions that increase the likelihood of ICH. Future developments, such as the introduction of oral direct thrombin inhibitors with more predictable pharmacokinetics than warfarin, may further improve the benefit‐to‐risk ratio of anticoagulation therapy for patients with AF.

Keywords: atrial fibrillation, stroke, intracranial hemorrhage, warfarin, anticoagulation

Full Text

The Full Text of this article is available as a PDF (82.7 KB).

References

  • 1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG: Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155: 469–473 [PubMed] [Google Scholar]
  • 2. Ryder KM, Benjamin EJ: Epidemiology and significance of atrial fibrillation. Am J Cardiol 1999; 84: 131R–138R [DOI] [PubMed] [Google Scholar]
  • 3. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC, Alonso‐Garcia A, Blomstrom‐Lundqvist C, De Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation): Developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001; 38: 1231–1266 [DOI] [PubMed] [Google Scholar]
  • 4. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Med Assoc 2001; 285: 2370–2375 [DOI] [PubMed] [Google Scholar]
  • 5. Kannel WB, Abbott RD, Savage DD, McNamara PM: Epidemiologic features of chronic atrial fibrillation: The Framingham study. N Engl J Med 1982; 1982: 1018–1022 [DOI] [PubMed] [Google Scholar]
  • 6. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987; 147: 1561–1564 [PubMed] [Google Scholar]
  • 7. Movsowitz HD, Lampert C, Jacobs LE, Kotler MN: Atrial fibrillation in the elderly: A review. Am J Geriatr Cardiol 1994; 3: 26–40 [PubMed] [Google Scholar]
  • 8. Taylor RD, Asinger RW: Atrial fibrillation: Clinical clues, keys to the workup. Consultant 1998; 38; 1865–1878 [Google Scholar]
  • 9. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983–988 [DOI] [PubMed] [Google Scholar]
  • 10. Lamassa M, Di Carlo AA, Pracucci G, Basile AM, Trefoloni G, Vanni P, Spolveri S, Baruffi MC, Landini G, Ghetti A, Wolfe CD, Inzitari D: Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: Data from a multicenter multinational hospital‐based registry (The European Community Stroke Project). Stroke 2001; 32: 392–398 [DOI] [PubMed] [Google Scholar]
  • 11. Lin HJ, Wolf PA, Kelly‐Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB: Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27: 1760–1764 [DOI] [PubMed] [Google Scholar]
  • 12. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C: Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349–355 [DOI] [PubMed] [Google Scholar]
  • 13. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornicki CC, Krause‐Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327: 1406–1412 [DOI] [PubMed] [Google Scholar]
  • 14. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B: Placebo‐controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175–179 [DOI] [PubMed] [Google Scholar]
  • 15. Stroke Prevention in Atrial Fibrillation Investigators : Stroke Prevention in Atrial Fibrillation Study: Final results. Circulation 1991; 84: 527–539 [DOI] [PubMed] [Google Scholar]
  • 16. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators : The effect of low‐dose warfarin on the risk of stroke in patients with non‐rheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505–1511 [DOI] [PubMed] [Google Scholar]
  • 17. EAFT (European Atrial Fibrillation Trial) Study Group : Secondary prevention in non‐rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–1262 [PubMed] [Google Scholar]
  • 18. Atrial Fibrillation Investigators : Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449–1457 [PubMed] [Google Scholar]
  • 19. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT: Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160: 41–46 [DOI] [PubMed] [Google Scholar]
  • 20. Brass LM, Krumholz HM, Scinto JM, Radford M: Warfarin use among patients with atrial fibrillation. Stroke 1997; 28: 2382–2389 [DOI] [PubMed] [Google Scholar]
  • 21. Gurwitz JH, Monette J, Rochon PA, Eckler MA, Avorn J: Atrial fibrillation and stroke prevention with warfarin in the long‐term care setting. Arch Intern Med 1997; 157: 978–984 [PubMed] [Google Scholar]
  • 22. Bungard TJ, Ghali WA, McAlister FA, Buchan AM, Cave AJ, Hamilton PG, Mitchell LB, Shuaib A, Teo KK, Tsuyuki RT: Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation. Can Med Assoc J 2001; 165: 301–302 [PMC free article] [PubMed] [Google Scholar]
  • 23. Cohen N, Almoznino‐Sarafian D, Alon I, Gorelik O, Koopfer M, Chachashvily S, Shteinshnaider M, Litvinjuk V, Modai D: Warfarin for stroke prevention still underused in atrial fibrillation: Patterns of omission. Stroke 2000; 31: 1217–1222 [DOI] [PubMed] [Google Scholar]
  • 24. Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta‐analysis. Ann Intern Med 1999; 131: 492–501 [DOI] [PubMed] [Google Scholar]
  • 25. Atwood JE, Albers GW: Anticoagulation and atrial fibrillation. Herz 1993; 18: 27–38 [PubMed] [Google Scholar]
  • 26. Atrial Fibrillation Investigators : Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998; 158: 1316–1320 [DOI] [PubMed] [Google Scholar]
  • 27. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE: Antithrombotic therapy in atrial fibrillation. Chest 1998; 114 (5 suppl): 579S–589S [DOI] [PubMed] [Google Scholar]
  • 28. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. J Am Med Assoc 2001; 285: 2864–2870 [DOI] [PubMed] [Google Scholar]
  • 29. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P: Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001; 119 (1 suppl): 300S–320S [DOI] [PubMed] [Google Scholar]
  • 30. Hart RG, Boop BS, Anderson DC: Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995; 26: 1471–1477 [DOI] [PubMed] [Google Scholar]
  • 31. Hylek EM, Go AA, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019–1026 [DOI] [PubMed] [Google Scholar]
  • 32. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM: Warfarin‐associated hemorrhage and cerebral amyloid angiopathy: A genetic and pathologic study. Neurology 2000; 55: 947–951 [DOI] [PubMed] [Google Scholar]
  • 33. Levine MN, Raskob G, Landefeld S, Kearon C: Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119 (1 suppl): 108S–121S [DOI] [PubMed] [Google Scholar]
  • 34. Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, Jacobson A, Deykin D, Matchar D: Managing oral anticoagulant therapy. Chest 2001; 119 (1 suppl): 22S–38S [DOI] [PubMed] [Google Scholar]
  • 35. Hylek EM, Singer DE: Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897–902 [DOI] [PubMed] [Google Scholar]
  • 36. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moja M, Ciavarella N, Devoto G, Berrettini M, Musolesi S, on behalf of the Italian Study on Complications of Oral Anticoagulant Therapy (ISCOAT): Bleeding complications of oral anticoagulant treatment : An inception‐cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423–428 [DOI] [PubMed] [Google Scholar]
  • 37. Gorter JW: Major bleeding during anticoagulation after cerebral ischemia: Patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology 1999; 53: 1319–1327 [DOI] [PubMed] [Google Scholar]
  • 38. Yamada M: Cerebral amyloid angiopathy: An overview. Neuropathology 2000; 20: 8–22 [DOI] [PubMed] [Google Scholar]
  • 39. Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW, Radford MJ: Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation. Stroke 2000; 31: 822–827 [DOI] [PubMed] [Google Scholar]
  • 40. Man‐Son‐Hing M, Nichol G, Lau A, Laupacis A: Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999; 159: 677–685 [DOI] [PubMed] [Google Scholar]
  • 41. Poller L, Shiach CR, MacCallum PK, Johansen AM, Munster AM, Magalhaes A, Jespersen J: Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet 1998; 352: 1505–1509 [DOI] [PubMed] [Google Scholar]
  • 42. Garabedian‐Ruffalo SM, Gray DR, Sax MJ, Ruffalo RL: Retrospective evaluation of a pharmacist‐managed warfarin anticoagulation clinic. Am J Hosp Pharm 1985; 42: 304–308 [PubMed] [Google Scholar]
  • 43. Wilt VM, Gums JG, Ahmed OI, Moore LM: Outcome analysis of a pharmacist‐managed anticoagulation service. Pharmacotherapy 1995; 15: 732–739 [PubMed] [Google Scholar]
  • 44. Falk RH: Atrial fibrillation. N Engl J Med 2001; 344: 1067–1078 [DOI] [PubMed] [Google Scholar]
  • 45. Maisel WH, Rawn JD, Stevenson WG: Atrial fibrillation after cardiac surgery. Ann Intern Med 2001; 135: 1061–1073 [DOI] [PubMed] [Google Scholar]
  • 46. Gruberg L: Survival of patients presenting with atrial fibrillation: The Atrial Fibrillation Follow‐up Investigation of Rhythm Management (AFFIRM) Study. Paper presented at: 51st Scientific Session of the American College of Cardiology, 2002;Atlanta, Georgia.
  • 47. Van Aken H, Bode C, Darius H, Diehm C, Encke A, Gulba DC, Haas S, Hacke W, Puhl W, Quante M, Riess H, Scharf R, Schellong S, Schror T, Schulte KL, Tebbe U: Anticoagulation: The present and future. Clin Appl Thromb Hemost 2001; 7: 195–204 [DOI] [PubMed] [Google Scholar]
  • 48. Stroke Prevention in Atrial Fibrillation Investigators : Adjusted‐dose warfarin versus low‐intensity, fixed‐dose warfarin plus aspirin for high‐risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633–638 [PubMed] [Google Scholar]
  • 49. Forfar JC: A 7‐year analysis of haemorrhage in patients on long‐term anticoagulant treatment. Br Heart J 1979; 42: 128–132 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Forfar JC: Prediction of hemorrhage during long‐term oral coumarin anticoagulation by excessive prothrombin ratio. Am Heart J 1982; 103: 445–446 [DOI] [PubMed] [Google Scholar]
  • 51. Landefeld CS, Goldman L: Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144–152 [DOI] [PubMed] [Google Scholar]
  • 52. Levine MN, Raskob G, Hirsch J: Hemorrhagic complications of long‐term anticoagulant therapy. Chest 1986; 89 (suppl): 15S–25S [DOI] [PubMed] [Google Scholar]
  • 53. Institute for Continuing Healthcare Education : Anticoagulation Therapy for Atrial Fibrillation: A Clinical Update 2002.
  • 54. Biblo LA, Yuan Z, Quan KJ, Mackall JA, Rimm AA: Risk of stroke in patients with atrial flutter. Am J Cardiol 2001; 87: 346–349 [DOI] [PubMed] [Google Scholar]
  • 55. Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, Sorensen H, Nagard S, Abrahamsson A, Bylund R: The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171–181 [DOI] [PubMed] [Google Scholar]
  • 56. Petersen P: A two‐year follow‐up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (abstr P06.131). Neurology 2002; 58 (suppl 3): A477 [Google Scholar]
  • 57. Erikkson UG, Johansson L, Frison L, Bredberg U, Gustafsson C: The pharmacokinetics of ximelagatran following single and repeated oral dosing to healthy male subjects (abstr P‐35). Blood Coagul Fibrinolysis 2001; 12: A28 [Google Scholar]
  • 58. Berkowitz SD: Antithrombotic therapy after prosthetic cardiac valve implantation: Potential novel antithrombotic therapies. Am Heart J 2001; 142: 7–13 [DOI] [PubMed] [Google Scholar]
  • 59. Petersen P, on behalf of the SPORTIF II and IV Investigators : A long‐term follow‐up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with atrial fibrillation (abstr 2953). Blood 2001; 98: 706a [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES